OT Pharma Fund IX, LLC
A fund vehicle, not an operating company. An investment fund or vehicle that filed a Form D, not an operating company.
Nothing material in the last 365 days. Last change: 26 Nov 2024, Filed a Form D on 26 Nov 2024: $3.37M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
- Nov 26, 2024Form D equity offering · $3.4M (form d sold) · 100 investorsFact Form D · “OT Pharma Fund IX, LLC filed Form D: $3,371,529 sold (indefinite offering), Other”
No firm portfolio page lists this company, so no outcome is stated.
- Nichola Eliovits Executive Officer sec.gov
Every observation on this company
- Entity type: Limited Liability Company Jan 3, 2025 Fact Form D
- Form D industry group: Other Jan 3, 2025 Fact Form D
- Amendment: false Jan 3, 2025 Fact Form D
- Revenue range (Form D): Not Applicable Jan 3, 2025 Fact Form D
- Incorporated: withinFiveYears Jan 3, 2025 Fact Form D
- Jurisdiction: Maryland Jan 3, 2025 Fact Form D
- Amount sold (Form D): $3.4M Jan 3, 2025 Fact Form D
- Exemptions: 06c Jan 3, 2025 Fact Form D
- First sale: 2024-11-26 Jan 3, 2025 Fact Form D
- Indefinite offering: true Jan 3, 2025 Fact Form D
- Investors (Form D): 100 Jan 3, 2025 Fact Form D
- Minimum investment (Form D): 100,000 Jan 3, 2025 Fact Form D
- Securities offered: pooled Jan 3, 2025 Fact Form D
- Office address: Jan 3, 2025 Fact Form D
- Year of incorporation: 2024 Jan 3, 2025 Fact Form D
Relationships across DFX
on 1 other DFX graph
OT Pharma Fund IX, LLC is the same institution as 1 record in RIA and Wealth.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Fund first reported on ADV2026-04-28source on record
- Form D filed2025-01-03source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.